

Fedor V Moiseyenko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8399545/publications.pdf>

Version: 2024-02-01

51
papers

6,979
citations

687220

13
h-index

434063

31
g-index

51
all docs

51
docs citations

51
times ranked

13513
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated genomic characterization of endometrial carcinoma. <i>Nature</i> , 2013, 497, 67-73.	13.7	4,075
2	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015, 161, 1681-1696.	13.5	2,562
3	Effect of silver oxide nanoparticles on tumor growth in vivo. <i>Doklady Biochemistry and Biophysics</i> , 2008, 421, 191-193.	0.3	54
4	High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma. <i>Onkologie</i> , 2010, 33, 231-238.	1.1	39
5	Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion. <i>F1000Research</i> , 2017, 6, 288.	0.8	25
6	Pulse mode of laser photodynamic treatment induced cell apoptosis. <i>Photodiagnosis and Photodynamic Therapy</i> , 2016, 13, 101-107.	1.3	24
7	Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer. <i>Investigational New Drugs</i> , 2020, 38, 894-898.	1.2	23
8	Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation. <i>Medical Oncology</i> , 2014, 31, 199.	1.2	20
9	Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. <i>European Journal of Cancer</i> , 2021, 152, 68-77.	1.3	18
10	Abnormal expression of ATP1A1 and ATP1A2 in breast cancer. <i>F1000Research</i> , 2017, 6, 10.	0.8	17
11	Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation. <i>Case Reports in Oncology</i> , 2019, 12, 339-343.	0.3	15
12	Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE). <i>Cancers</i> , 2021, 13, 2529.	1.7	15
13	Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants. <i>Biochimie</i> , 2018, 154, 19-24.	1.3	14
14	Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4881-4887.	3.2	10
15	High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation. <i>Medical Oncology</i> , 2015, 32, 89.	1.2	8
16	First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients. <i>Clinical Drug Investigation</i> , 2018, 38, 553-562.	1.1	8
17	EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts. <i>Oncology Research and Treatment</i> , 2018, 41, 634-642.	0.8	8
18	Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression. <i>Oncology Research and Treatment</i> , 2016, 39, 605-614.	0.8	6

#	ARTICLE	IF	CITATIONS
19	Overall Survival of Patients With ALK-Positive Metastatic Non-Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort Study. <i>Journal of Global Oncology</i> , 2019, 5, 1-7.	0.5	6
20	Crystal structures of a llama VHH antibody BCD090-M2 targeting human ErbB3 receptor. <i>Research</i> , 2018, 7, 57.	0.8	6
21	“Lazarus Response” to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion. <i>Cureus</i> , 2018, 10, e2150.	0.2	5
22	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. <i>Journal of Modern Oncology</i> , 2021, 23, 369-402.	0.1	5
23	Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100524.	0.7	5
24	Rapid Symptomatic Improvement in Gefitinib-Treated Patients with EGFR-Mutated Lung Cancer: Possible Role of Downregulation of Inflammatory Molecules?. <i>Onkologie</i> , 2011, 34, 559-560.	1.1	3
25	Metastasectomy in colorectal carcinoma (CRC) patients (pts) with mBRAF: Prospective database analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15549-e15549.	0.8	1
26	Observational study of the efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14593-e14593.	0.8	1
27	Efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim results of observational prospective study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21126-e21126.	0.8	1
28	Incidence and prognostic factors in patients (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15035-e15035.	0.8	1
29	Aflibercept (Afl) for patients (pts) with metastatic colorectal cancer (mCRC): Clinical predictors of nonhematologic (nonhem) toxicity.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15007-e15007.	0.8	1
30	Russian multicenter experience of using talazoparib in the treatment of patients with BRCA-associated metastatic breast cancer. <i>Meditinskiy Sovet</i> , 2020, , 143-146.	0.1	1
31	Tumor irradiation may facilitate the detection of tumor-specific mutations in plasma. <i>World Journal of Clinical Oncology</i> , 2021, 12, 1215-1226.	0.9	1
32	Antitumor efficacy of an isolated hind leg perfusion with a pH-increased solution in the Pliss™ lymphosarcoma graft rat model. <i>Almanah Klinicheskoy Meditsiny</i> , 2021, 49, 541-549.	0.2	1
33	Evaluation of Immunosuppressive Surface Molecules, Essential for Resistance to CAR T-Cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S300.	0.2	0
34	Incidence of Synchronous Multiple Primary Melanoma in Patients with Solitary Melanoma: a Prospective Comparative Study. <i>Kreativna i Hirurgicheskaya Onkologiya</i> , 2021, 11, 118-124.	0.1	0
35	Efficacy of Videoendoscopic Inguinal Femoral Lymphadenectomy for Management of Metastatic Skin Melanoma. <i>Kreativna i Hirurgicheskaya Onkologiya</i> , 2021, 11, 138-143.	0.1	0
36	Effectiveness of a shortened cycle of monoimmunotherapy in NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21179-e21179.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Comprehensive Screening for COVID-19 at St. Petersburg Oncology Centre. KreativnaĀ HirurgiĀ I OnkologiĀ, 2021, 11, 109-117.	0.1	0
38	Efficacy of first-line treatments for patients (pts) with advanced EGFR mutated NSCLC: Network meta-analysis of TKI monotherapy and combinations trials.. Journal of Clinical Oncology, 2021, 39, e21120-e21120.	0.8	0
39	Bladder cancer. A retrospective analysis of the use of vinflavin in real clinical practice. IssledovaniĀ I Praktika V Medicine, 2021, 8, 34-42.	0.1	0
40	Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report. Journal of Modern Oncology, 2021, 23, 287-291.	0.1	0
41	Clinical cases of pembrolisumab immunotherapy treatment in patients with non-small lung cancer with high level of PD-L1 expression in fist line therapy. Medical Alphabet, 2021, , 8-11.	0.0	0
42	Therapeutic effect of gemcitabine on experimental tumors of the brain.. Journal of Clinical Oncology, 2013, 31, e13005-e13005.	0.8	0
43	CELLULAR IMMUNE REACTION IN A GREAT OMENTUM WITH METASTASES IN PATIENTS WITH OVARIAN CANCER. KreativnaĀ HirurgiĀ I OnkologiĀ, 2018, 8, 39-44.	0.1	0
44	Mineralization of the Peritoneum â€” a New Target in the Treatment of Peritoneal Carcinomatosis. KreativnaĀ HirurgiĀ I OnkologiĀ, 2019, 8, 279-284.	0.1	0
45	Multicenter observational prospective study of nivolumab (Nivo) as 2+ line treatment in advanced refractory NSCLC pts: Clinical and quality of life outcomes.. Journal of Clinical Oncology, 2019, 37, e20567-e20567.	0.8	0
46	Āonfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer. Meditsinskiy Sovet, 2020, , 47-52.	0.1	0
47	399â€¦Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial. , 2020, , .		0
48	Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer. International Journal of Clinical Oncology, 2022, , 1.	1.0	0
49	Comparison of the treatment results in patients with inoperable non-small cell lung cancer in clinical trials and in standard clinical practice using the pseudorandomization method. AlĀmanah KliniĀeskoj Mediciny, 0, , .	0.2	0
50	Multicenter prospective observational post-approval study of safety and efficacy of bevacizumab (AvegraĀ, BIOCAD) in patients with metastatic colorectal cancer in real world practice: APOLLON-11 and SOYUZ-APOLLON. Journal of Modern Oncology, 2021, 23, 695-702.	0.1	0
51	Prevalence of iron deficiency anemia in patients with metastatic colorectal cancer. AlĀmanah KliniĀeskoj Mediciny, 2022, 50, 65-70.	0.2	0